Drugs / Refresh Tears
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials | ||||||
| Phase 4 | NCT01128556 | Apr → Jun 2010 | allergic disease | North Texas Institute for Clinical Trials | Completed | No outcome recorded |
| Phase 4 | NCT00284999 | ? → Aug 2006 | dry eye syndrome | Pharmaceutical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00469521 | — | — | Innovative Medical | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT01382810 Comparator | Mar 2011 → Oct 2012 | dry eye syndrome | Innovative Medical | Unknown | No outcome recorded |
| Phase 4 | NCT01227226 Comparator | Oct 2010 → Mar 2011 | dry eye syndrome | Hom, Milton M., OD, FAAO | Unknown | No outcome recorded |
| Phase 4 | NCT00634972 Background | Nov 2005 → Aug 2008 | blindness (disorder), retinal detachment, retinopathy of prematurity | University of South Alabama | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REFRESH TEARS | “Allergan's Refresh tears artificial tear” NCT01227226 ↗ |
| Known as | Allergan Refresh Tears | “To determine baseline tear thickness and improvement immediately post installation of two artificial tear solutions:(9582X) and Allergan Refresh Tears.” NCT00469521 ↗ |
| Route | Topical | “Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment” NCT01128556 ↗ |